What Does Humana Do?
Founded in 1961 and headquartered in Louisville, Kentucky, Humana is one of the largest managed healthcare companies in the United States. It operates in two segments: Insurance (Medicare Advantage, Medicaid, commercial plans, military/TRICARE services) and CenterWell (pharmacy benefit management, senior-focused primary care centres, and home health services). With 35 years as a public company, Humana has historically been a blue-chip healthcare compounder — but the past two years have seen a structural deterioration in its core Medicare Advantage margins.
BQ Score — Business Quality
Humana's BQ score is assessed on a compressed 15-point scale due to data availability. The scores reflect recent deterioration in margins and cash flow — this is not a stable-quality business at this moment.
The Margin Crisis
The core problem at Humana is simple: medical costs are rising faster than premiums. The Benefit Ratio (what percentage of premiums go to paying medical claims) has surged. In Q3 2025, the Insurance Segment Benefit Ratio hit 91.1% — meaning Humana spent $91.10 paying claims for every $100 it collected in premiums. Operating margins have collapsed from 2% in FY2024 to just 1.2% in Q3 2025.
| Period | Rev Growth | Op Margin | Benefit Ratio | Net Margin |
|---|
| FY 2024 | +11% | 2% | 90.4% | 3% |
| Q1 2025 | +8.4% | 6% | 87.4% | 5% |
| Q2 2025 | +10% | 3.3% | 89.9% | 3% |
| Q3 2025 | +11% | 1.2% | 91.1% | 3% |
The Star Rating Problem
CMS Star Ratings determine the bonuses Medicare Advantage plans receive from the government. Humana's Star ratings have degraded, and a US judge rejected its legal challenge to the 2025 ratings. Lower Stars = fewer bonus payments = direct revenue and margin hit. This is not just an accounting issue — it flows directly to the income statement.
Membership Growth Slowing
Humana expects only ~160,000 Medicaid membership additions in 2025, down from prior guidance of 175,000–250,000. Management is intentionally prioritising profit over growth — which is the right strategic call, but it reduces the near-term growth story.
CenterWell — The Hidden Asset
CenterWell (home health, pharmacy, senior care) represents a growing, higher-margin business within Humana. It is less exposed to the Medicare Advantage repricing cycle and has been growing revenue at 35–52% year-on-year in recent quarters. Long-term, this segment de-risks the pure-insurance model.
Analyst View
27 analysts cover HUM — 9 Buy, 18 Hold. Price targets range from $215 to $353, averaging $287.38 against a current price of $277.57. The split consensus reflects genuine uncertainty about the Star rating recovery timeline and medical cost normalisation. Revenue growth projections remain modest: 9.72% for 2025, 11.92% for 2026.
Easy Equity Verdict
A quality franchise in a temporary — but painful — reset. Track, don't buy yet.
Humana is a fundamentally strong business caught in a structural repricing cycle. The Medicare Advantage system forces insurers to set premiums a year in advance, and Humana mispriced its cost assumptions in 2023–2024. It is now paying the price. The recovery thesis is real — if Stars stabilise, if medical cost trends normalise, and if CenterWell continues to grow — but multiple things need to go right simultaneously. We prefer to wait for at least two consecutive quarters of improving benefit ratios before considering entry.